Xilio Therapeutics (XLO) Non-Current Assets (2020 - 2026)
Xilio Therapeutics (XLO) posted Non-Current Assets of $9.3 million for Q1 2026, down 3.91% sequentially from $9.7 million in Q4 2025, and down 11.75% YoY from $10.5 million in Q1 2025.
Xilio Therapeutics (XLO) Non-Current Assets (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $9.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 11.75% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.6 million (down 13.31% YoY) and the FY2025 annual result came in at $9.7 million, down 10.91% from the prior year.
- Non-Current Assets retreated to $9.3 million in Q1 2026 per XLO's latest filing, from $9.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $15.3 million in Q1 2022 and troughed at $9.3 million in Q1 2026.
- A 5-year average of $12.4 million and a median of $12.8 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets dropped 0.35% in 2022, then decreased 21.66% in 2025.
- Over 5 years, Non-Current Assets stood at $14.7 million in 2022, then slipped by 12.75% to $12.8 million in 2023, then decreased by 15.3% to $10.8 million in 2024, then slipped by 10.91% to $9.7 million in 2025, then declined by 3.91% to $9.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $9.3 million, $9.7 million, and $9.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 18.06 Bn |
| 10 | Xilio Therapeutics | 177.07 Mn | 41.03 Mn | - | 8.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.79 Mn |
| Mar 31, 2026 | 9.28 Mn |
| Dec 31, 2025 | 9.66 Mn |
| Sep 30, 2025 | 9.61 Mn |
| Jun 30, 2025 | 10.10 Mn |
| Mar 31, 2025 | 10.52 Mn |
| Dec 31, 2024 | 10.84 Mn |
| Sep 30, 2024 | 11.35 Mn |
| Jun 30, 2024 | 11.87 Mn |
| Mar 31, 2024 | 13.42 Mn |
| Dec 31, 2023 | 12.80 Mn |
| Sep 30, 2023 | 13.36 Mn |
| Jun 30, 2023 | 13.93 Mn |
| Mar 31, 2023 | 14.53 Mn |
| Dec 31, 2022 | 14.67 Mn |
| Sep 30, 2022 | 15.10 Mn |
| Jun 30, 2022 | 15.12 Mn |
| Mar 31, 2022 | 15.27 Mn |
| Dec 31, 2021 | 15.54 Mn |
| Sep 30, 2021 | 15.15 Mn |